Ani Pharmaceuticals Inc (ANIP) valuation
Ani Pharmaceuticals P/E ratio history
Ani Pharmaceuticals trades at 15.7 times its earnings over the last twelve months and 7.4 times the earnings analysts expect over the next twelve. At its last 5 fiscal year ends its P/E ranged from 23.8 (year to Dec 2025) to 173.2 (year to Dec 2016), with a median of 64.9.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $78.94 | $3.32 | 23.8 | 9.7 |
| Dec 31, 2024 | $55.28 | -$1.04 | n/m | 10.8 |
| Dec 31, 2023 | $55.14 | $0.85 | 64.9 | 12.9 |
| Dec 31, 2022 | $40.23 | -$3.05 | n/m | — |
| Dec 31, 2021 | $46.08 | -$3.40 | n/m | — |
| Dec 31, 2020 | $29.04 | -$1.88 | n/m | — |
| Dec 31, 2019 | $61.67 | $0.48 | 128.5 | — |
| Dec 31, 2018 | $45.02 | $1.30 | 34.6 | — |
| Dec 31, 2017 | $64.45 | -$0.10 | n/m | — |
| Dec 31, 2016 | $60.62 | $0.35 | 173.2 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Ani Pharmaceuticals valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Ani PharmaceuticalsANIP | $1.64B | 15.7 | 7.4 | 1.7 |
| Stoke TherapeuticsSTOK | $1.64B | — | — | 59.3 |
| Sonida Senior LivingSNDA | $1.62B | — | — | 3.1 |
| PersonalisPSNL | $1.66B | — | — | 23.8 |
| NovavaxNVAX | $1.66B | — | — | 4.0 |
| Replimune GroupREPL | $1.66B | — | — | — |
| Nuvation BioNUVB | $1.66B | — | — | 9.8 |
| OmnicellOMCL | $1.67B | 43.6 | 17.1 | 1.3 |
| Urogen PharmaURGN | $1.59B | — | 28.0 | 8.5 |
| Peer median | 43.6 | 22.5 | 8.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ANIP financials · ANIP returns
No forecast, no recommendation. This page describes Ani Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.